Skip to content

Janux Therapeutics

US · JANX #3187 by market cap Listed 2021
17.92 +1.13 +6.73%
Live - 5344 symbols - heartbeat 470s ago · 2026-10-08 08:14
Pre-market 18.42 +2.79%
After-hours 18.50 +3.24%
Overnight 17.91 -0.06%
Market cap
1.10B
P/B
1.18
EPS
-1.83
Reader sentiment Are you bullish or bearish on JANX?

Anonymous reader poll. Unscientific, not investment advice.

About Janux Therapeutics

Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.

Founded
2017
CEO
Dr. David Campbell, PhD
Employees
109
Headquarters
La Jolla, California, United States of America
Fiscal year end
12-31
Website
januxrx.com

Company profile

Exchange
US
Symbol
JANX
Market-cap rank
#3187
Listing date
2021-06-11
Market cap
1.10B
Float cap
762.06M
Shares out
61.14M
Float shares
42.53M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:14:51 · For reference only, not investment advice and not tailored to your situation.